Dr Kohei Shitara speaks to ecancer as part of ASCO GI 2023 about his study looking at zolbetuximab plus mFOLFOX6 as first-line treatment for CLDN18.2+/ HER2 metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma.

He explains that patients were randomised 1:1 to zolbetuximab plus mFOLFOX6 or placebo plus mFOLFOX6.

Dr Shitara reports that PFS was significantly improved with zolbetuximab, a statistically significant 10.6 months compared with 8.7 months.